Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social Vulnerability Hinders Clinical Trial Participation in Gastrointestinal Cancer Surgery Patients.

Annals of surgery·2025
Same author

Resistant gastroenteropancreatic neuroendocrine tumors: a definition and guideline to medical and surgical management.

Proceedings (Baylor University. Medical Center)·2024
Same author

Rutgers Cancer Institute of New Jersey's Community Outreach and Engagement Approach to Cancer Prevention.

Cancer prevention research (Philadelphia, Pa.)·2023
Same author

Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis.

Cancer research communications·2023
Same author

A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection.

PloS one·2023
Same author

A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.

Investigational new drugs·2022
Same journal

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.

Future oncology (London, England)·2026
Same journal

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.

Future oncology (London, England)·2026
Same journal

Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 cases.

Future oncology (London, England)·2026
Same journal

VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.

Future oncology (London, England)·2026
Same journal

Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy.

Future oncology (London, England)·2026
Same journal

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Future oncology (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head
05:42

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head

Published on: January 3, 2020

Insulinoma: pathophysiology, localization and management.

Joyce J Shin1, Phillip Gorden, Steven K Libutti

  • 1Montefiore Medical Center/Albert Einstein College of Medicine, Greene Medical Arts Pavilion, Bronx, NY 10467, USA. jshin@montefiore.org

Future Oncology (London, England)
|February 12, 2010
PubMed
Summary
This summary is machine-generated.

Insulinoma, a rare tumor causing low blood sugar, is typically benign and curable with surgery. Early diagnosis and localization are key for effective management, including laparoscopic approaches.

More Related Videos

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

Staining Protocols for Human Pancreatic Islets
07:48

Staining Protocols for Human Pancreatic Islets

Published on: May 23, 2012

Related Experiment Videos

Last Updated: Jun 16, 2026

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head
05:42

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head

Published on: January 3, 2020

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

Staining Protocols for Human Pancreatic Islets
07:48

Staining Protocols for Human Pancreatic Islets

Published on: May 23, 2012

Area of Science:

  • Endocrinology
  • Surgical Oncology
  • Oncology

Background:

  • Insulinoma is a rare neuroendocrine tumor leading to hyperinsulinism and hypoglycemia.
  • While often sporadic, insulinomas can be associated with Multiple Endocrine Neoplasia type-1.
  • Most insulinomas are benign, solitary, and have favorable surgical cure rates.

Purpose of the Study:

  • To provide a comprehensive review of insulinoma.
  • To discuss historical background, pathogenesis, and diagnosis.
  • To cover localization and management strategies, including surgical options.

Main Methods:

  • Review of existing literature on insulinoma.
  • Discussion of diagnostic methods, including supervised fasting.
  • Analysis of various preoperative and intraoperative localization techniques.
  • Evaluation of surgical management options, including enucleation and resection.
  • Exploration of the role of laparoscopic surgery.

Main Results:

  • Insulinomas are characterized by insulin hypersecretion and hypoglycemic symptoms.
  • Diagnosis is confirmed via supervised fasting.
  • Surgical intervention, particularly tumor enucleation, is the primary treatment.
  • Laparoscopic surgery is increasingly relevant for insulinoma management.

Conclusions:

  • Insulinoma management requires accurate diagnosis and localization for successful surgical outcomes.
  • Surgical cure rates are high, especially for benign and solitary tumors.
  • The review highlights the evolving role of minimally invasive techniques in treating insulinoma.